Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, Fox EA, Antonescu CR, Fletcher CD, Guo X, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA.

Nat Genet. 2014 Jun;46(6):601-6. doi: 10.1038/ng.2974. Epub 2014 May 4.

2.

Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors.

Pantaleo MA, Astolfi A, Urbini M, Fuligni F, Saponara M, Nannini M, Lolli C, Indio V, Santini D, Ercolani G, Brandi G, Pinna AD, Biasco G.

Clin Sarcoma Res. 2014 Aug 9;4:9. doi: 10.1186/2045-3329-4-9. eCollection 2014.

3.

DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies.

Schmidt WM, Uddin MH, Dysek S, Moser-Thier K, Pirker C, Höger H, Ambros IM, Ambros PF, Berger W, Bittner RE.

PLoS Genet. 2011 Apr;7(4):e1002042. doi: 10.1371/journal.pgen.1002042. Epub 2011 Apr 14.

4.

Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma.

Hosur V, Kavirayani A, Riefler J, Carney LM, Lyons B, Gott B, Cox GA, Shultz LD.

Cancer Genet. 2012 May;205(5):232-41. doi: 10.1016/j.cancergen.2012.03.005.

5.

Expression of the dystrophin isoform Dp71 in differentiating human fetal myogenic cultures.

Tennyson CN, Dally GY, Ray PN, Worton RG.

Hum Mol Genet. 1996 Oct;5(10):1559-66.

PMID:
8894689
6.

Cell cycle and dystrophin dysregulation in GIST.

Wang Y, Fletcher JA.

Cell Cycle. 2015;14(17):2713-4. doi: 10.1080/15384101.2015.1064676. Epub 2015 Jun 23. No abstract available.

7.

[Muscular dystrophies detected by immunophenotyping and genotype analysis (mRNA and DNA)].

Lukás Z, Vojtísková M, Fajkusová L, Bednarík J, Kadanka Z, Hájek J, Hermanová M, Vohánka S, Vytopil M.

Cesk Patol. 2001 Nov;37(4):137-45. Czech.

PMID:
11813630
8.

PGD for dystrophin gene deletions using fluorescence in situ hybridization.

Malmgren H, White I, Johansson S, Levkov L, Iwarsson E, Fridström M, Blennow E.

Mol Hum Reprod. 2006 May;12(5):353-6. Epub 2006 Apr 11.

PMID:
16608904
9.

Engraftment of mesenchymal stem cells into dystrophin-deficient mice is not accompanied by functional recovery.

Gang EJ, Darabi R, Bosnakovski D, Xu Z, Kamm KE, Kyba M, Perlingeiro RC.

Exp Cell Res. 2009 Sep 10;315(15):2624-36. doi: 10.1016/j.yexcr.2009.05.009. Epub 2009 May 19.

PMID:
19460366
10.

Recent developments in the biology of dystrophin and related molecules.

Karpati G.

Curr Opin Neurol Neurosurg. 1992 Oct;5(5):615-21. Review.

PMID:
1392135
11.

Proportion and pattern of dystrophin gene deletions in north Indian Duchenne and Becker muscular dystrophy patients.

Singh V, Sinha S, Mishra S, Chaturvedi LS, Pradhan S, Mittal RD, Mittal B.

Hum Genet. 1997 Feb;99(2):206-8.

PMID:
9048922
12.

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour.

Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee CH, Steigen SE, Zhu S, Montgomery KD, Lazar AJ, Lev D, Fletcher JA, Beck AH, West RB, Nusse R, van de Rijn M.

J Pathol. 2012 Jun;227(2):223-33. doi: 10.1002/path.3986. Epub 2012 Feb 17.

13.

Dystrophin expression in Duchenne patients with "in-frame" gene deletions.

Nicholson LV, Bushby KM, Johnson MA, Gardner-Medwin D, Ginjaar IB.

Neuropediatrics. 1993 Apr;24(2):93-7.

PMID:
8327067
14.

[In vitro transformation of amniotic cells to muscle cells--background and outlook].

Streubel B, Martucci-Ivessa G, Fleck T, Bittner RE.

Wien Med Wochenschr. 1996;146(9-10):216-7. German.

PMID:
9012220
15.

Detection of DMD gene deletions in Thai children patients.

Kamolsilp M, Paditaporn R, Noonai A, Wasant P.

Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:172-4.

PMID:
8629100
16.

Secondary reduction of alpha7B integrin in laminin alpha2 deficient congenital muscular dystrophy supports an additional transmembrane link in skeletal muscle.

Cohn RD, Mayer U, Saher G, Herrmann R, van der Flier A, Sonnenberg A, Sorokin L, Voit T.

J Neurol Sci. 1999 Mar 1;163(2):140-52.

PMID:
10371075
17.

Clinical diagnosis of heterozygous dystrophin gene deletions by fluorescence in situ hybridization.

Rosenberg C, Navajas L, Vagenas DF, Bakker E, Vainzof M, Passos-Bueno MR, Takata RI, Van Ommen GJ, Zatz M, Den Dunnen JT.

Neuromuscul Disord. 1998 Oct;8(7):447-52.

PMID:
9829273
18.

Nitric oxide generated by muscle corrects defects in hippocampal neurogenesis and neural differentiation caused by muscular dystrophy.

Deng B, Glanzman D, Tidball JG.

J Physiol. 2009 Apr 15;587(Pt 8):1769-78. doi: 10.1113/jphysiol.2008.166256. Epub 2009 Feb 23.

19.

Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy.

Araki E, Nakamura K, Nakao K, Kameya S, Kobayashi O, Nonaka I, Kobayashi T, Katsuki M.

Biochem Biophys Res Commun. 1997 Sep 18;238(2):492-7.

PMID:
9299538
20.

BMP4 inhibits myogenic differentiation of bone marrow-derived mesenchymal stromal cells in mdx mice.

Jiqing C, Yaqin L, Yingyin L, Fei C, Huili Z, Yuling Z, Juan Y, Shanwei F, Cheng Z.

Cytotherapy. 2015 Sep;17(9):1213-9. doi: 10.1016/j.jcyt.2015.06.010.

Supplemental Content

Support Center